Search
01/01/2022
CDK5RAP3, a New BRCA2 Partner That Regulates DNA Repair, Is Associated with Breast Cancer Survival
Minguillon, J, Ramirez, MJ, Rovirosa, L, Bustamante-Madrid, P, Camps-Fajol, C, de Garibay, GR, Shimelis, H, Montanuy, H, Pujol, R, Hernandez, G, Bogliolo, M, Castillo, P, Soucy, P, Martrat, G, Gomez, A, Cuadras, D, Garcia, MJ, Gayarre, J, Lazaro, C, Benitez, J, Couch, FJ, Pujana, MA, Surralles, J. CDK5RAP3, a New BRCA2 Partner That Regulates DNA Repair, Is Associated with Breast Cancer Survival. Cancers. 2022; 14(2)DOI:10.3390/cancers14020353. PMID:35053516. IF:5.200(Q2/3D).
01/01/2022
Genomic signature of Fanconi anaemia DNA repair pathway deficiency in cancer
Webster A.L.H., Sanders M.A., Patel K., Dietrich R., Noonan R.J., Lach F.P., White R.R., Goldfarb A., Hadi K., Edwards M.M., Donovan F.X., Hoogenboezem R.M., Jung M., Sridhar S., Wiley T.F., Fedrigo O., Tian H., Rosiene J., Heineman T., Kennedy J.A., Bean L., Rosti R.O., Tryon R., Gonzalez A.-M., Rosenberg A., Luo J.-D., Carroll T.S., Shroff S., Beaumont M., Velleuer E., Rastatter J.C., Wells S.I., Surrallés J., Bagby G., MacMillan M.L., Wagner J.E., Cancio M., Boulad F., Scognamiglio T., Vaughan R., Beaumont K.G., Koren A., Imielinski M., Chandrasekharappa S.C., Auerbach A.D., Singh B., Kutler D.I., Campbell P.J., Smogorzewska A.. Genomic signature of Fanconi anaemia DNA repair pathway deficiency in cancer. NATURE. 2022; 612(7940)DOI:10.1038/s41586-022-05253-4. PMID:36450981. IF:64.800(Q1/1D).
01/01/2022
Development of a mouse model for spontaneous oral squamous cell carcinoma in Fanconi anemia
Errazquin R., Page A., Suñol A., Segrelles C., Carrasco E., Peral J., Garrido-Aranda A., Del Marro S., Ortiz J., Lorz C., Minguillon J., Surralles J., Belendez C., Alvarez M., Balmaña J., Bravo A., Ramirez A., Garcia-Escudero R.. Development of a mouse model for spontaneous oral squamous cell carcinoma in Fanconi anemia. ORAL ONCOLOGY. 2022; 134DOI:10.1016/j.oraloncology.2022.106184. PMID:36191479. IF:4.800(Q1/1D).
01/01/2022
SELNET clinical practice guidelines for soft tissue sarcoma and GIST
Blay, JY, Hindi, N, Bollard, J, Aguiar, S, Angel, M, Araya, B, Badilla, R, Bernabeu, D, Campos, F, Caro-Sanchez, CHS, Carvajal, B, Montoya, AC, Casavilca-Zambrano, S, Castro-Oliden, V, Chacon, M, Clara, M, Collini, P, Genoroso, RC, Costa, FD, Cuellar, M, dei Tos, AP, Malagon, HRD, Donati, D, Dufresne, A, Eriksson, M, Farias-Loza, M, Fernandez, P, Frezza, AM, Frisoni, T, Garcia-Ortega, DY, Gelderblom, H, Gouin, F, Gomez-Mateo, MC, Gronchi, A, Haro, J, Huanca, L, Jimenez, N, Karanian, M, Kasper, B, David, BBL, Lopez-Pousa, A, Lutter, G, Martinez-Said, H, Martinez-Tlahuel, J, Mello, CA, Perez, JMM, David, SM, Nascimento, AG, Ortiz-Cruz, EJ, Palmerini, E, Patel, S, Pfluger, Y, Provenzano, S, Righi, A, Rodriguez, A, Salas, R, Santos, TTG, Scotlandi, K, Soule, T, Stacchiotti, S, Valverde, C, Waisberg, F, Estrada, EZ, Martin-Broto, J. SELNET clinical practice guidelines for soft tissue sarcoma and GIST. CANCER TREATMENT REVIEWS. 2022; 102DOI:10.1016/j.ctrv.2021.102312. PMID:34798363. IF:11.800(Q1/1D).
01/01/2022
Seroprevalence and immunological memory against SARS-CoV-2 in lung cancer patients: the SOLID study
Provencio, M, Rodriguez-Abreu, D, Ortega, AL, Serrano, G, Aguado, C, Franco, F, Gutierrez, V, Vivanco, GL, Guirado, M, Benitez, G, Estival, A, Calvo, V, Jimenez, B, Arasanz, H, Coves, J, Majem, M, Massuti, B, Vazquez, S, Juan-Vidal, O, Collazo-Lorduy, A, Gozalvez, CL, Del Barco, E, Rosero, A, Bosch-Barrerra, J, Moreno, MA, Mielgo-Rubio, X, Villa, JC, Lopez-Martin, A, Cordoba, JF, Aparisi, FD, Zafra, M, Mosquera, J, Altozano, JP, Nadal, E, Catot, S, Balsalobre, J, De Portugal, T, Martin, P, De Juan, SC, Cobo, M. Seroprevalence and immunological memory against SARS-CoV-2 in lung cancer patients: the SOLID study. Translational Lung Cancer Research. 2022; 11(1)DOI:10.21037/tlcr-21-504. PMID:35242627. IF:4.000(Q2/4D).
01/01/2022
A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer
Kuemmel, S, Campone, M, Loirat, D, Lopez, RL, Beck, JT, De Laurentiis, M, Im, SA, Kim, SB, Kwong, A, Steger, GG, Adelantado, EZ, Duhoux, FP, Greil, R, Kuter, I, Lu, YS, Tibau, A, Ozguroglu, M, Scholz, CW, Singer, CF, Vega, E, Wimberger, P, Zamagni, C, Couillebault, XM, Fan, LQ, Guerreiro, N, Mataraza, J, Sand-Dejmek, J, Chan, A. A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer. CLINICAL CANCER RESEARCH. 2022; 28(1)DOI:10.1158/1078-0432.CCR-20-3955. PMID:34615719. IF:11.500(Q1/1D).
01/01/2022
Clinical benefit of cancer drugs approved in Switzerland 2010-2019
Adam, R, Tibau, A, Valiente, CM, Seruga, B, Ocana, A, Amir, E, Templeton, AJ. Clinical benefit of cancer drugs approved in Switzerland 2010-2019. PLoS One. 2022; 17(6)DOI:10.1371/journal.pone.0268545. PMID:35687539. IF:3.700(Q2/4D).
01/01/2022
CES1 and SLC6A2 Genetic Variants As Predictors of Response To Methylphenidate in Autism Spectrum Disorders
Hernandez, MH, Bote, V, Serra-LLovich, A, Cendros, M, Salazar, J, Mestres, C, Guijarro, S, Alvarez, A, Lamborena, C, Mendez, I, Sanchez, B, Hervas, A, Arranz, MJ. CES1 and SLC6A2 Genetic Variants As Predictors of Response To Methylphenidate in Autism Spectrum Disorders. Pharmacogenomics & Personalized Medicine. 2022; 15DOI:10.2147/PGPM.S377210. PMID:36393977. IF:1.900(Q4/9D).